Sophiris Bio (SPHS) Stock Price, News & Analysis

Company Overview

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $4,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SPHS Stock Analysis - Frequently Asked Questions

How were Sophiris Bio's earnings last quarter?

Sophiris Bio, Inc. (OTCMKTS:SPHS) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02.

How do I buy shares of Sophiris Bio?

Shares of SPHS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sophiris Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sophiris Bio investors own include Sarepta Therapeutics (SRPT), Intercept Pharmaceuticals (ICPT), (CPXX) (CPXX), SELLAS Life Sciences Group (SLS), Advanced Micro Devices (AMD), Rigel Pharmaceuticals (RIGL) and Anavex Life Sciences (AVXL).

Company Calendar

• Last Earnings: 5/09/2019
• Today: 4/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:SPHS
• CIK: 1563855
• Web: www.sophirisbio.com
• Phone: (858) 777-1760
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,550,000
• Free Float: N/A
• Market Cap: $4,000.00
• Optionable: Not Optionable
• Beta: 1.94